Clinical Research Directory
Browse clinical research sites, groups, and studies.
to Evaluate the Safety and the Pharmacokinetic and Pharmacodynamic Interactions Between JP-1366 and Clopidogrel, Aspirin, Atorvastatin and Apixaban
Sponsor: Onconic Therapeutics Inc.
Summary
to Evaluate the Safety and the Pharmacokinetic and Pharmacodynamic Interactions between JP-1366 and Clopidogrel, Aspirin, Atorvastatin and Apixaban
Official title: A Phase 1 Clinical Trial to Evaluate the Safety and the Pharmacokinetic and Pharmacodynamic Interactions Between JP-1366 and Clopidogrel, Aspirin, Atorvastatin and Apixaban in Healthy Volunteers.
Key Details
Gender
All
Age Range
19 Years - 64 Years
Study Type
INTERVENTIONAL
Enrollment
96
Start Date
2025-11-17
Completion Date
2026-03-30
Last Updated
2025-12-04
Healthy Volunteers
Yes
Conditions
Interventions
JP-1366 and clopidogrel
A randomized, open label, multiple-dosing, 6-sequence, 3-period, 3-treatment, crossover design
JP-1366 and aspirin
An open-label, multiple-dosing, fixed sequence, 3-period design
JP-1366 and atorvastatin
An open-label, multiple-dosing, fixed sequence, 3-period design Period 1: Atorvastatin
JP-1366 and apixaban
An open-label, multiple-dosing, fixed sequence, 3-period design
Locations (1)
Cha University Bundang Medical Center
Seongnam-si, Gyeonggi-do, South Korea